Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spiriva Finds COPD Exacerbation Studies Can Be An Exasperating Experience

This article was originally published in The Pink Sheet Daily

Executive Summary

As competitors tout comparative data, Boehringer hopes a Nov. 19 advisory committee on its claim for reduction in exacerbations will lead to a broader label.

You may also be interested in...



Spiriva Safety Debate Pits Clinical Study Results Against Meta-Analysis

FDA also asks advisory panel to assess mixed efficacy results for BI's drug to reduce exacerbation of chronic obstructive pulmonary disease.

Spiriva Safety Debate Pits Clinical Study Results Against Meta-Analysis

FDA also asks advisory panel to assess mixed efficacy results for BI's drug to reduce exacerbation of chronic obstructive pulmonary disease.

Good Showing For Nycomed's COPD Drug Daxas

Reports in the Aug. 27 Lancet look good for the novel phosphodiesterase-4 inhibitor, under consideration by U.S. and EU regulators.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel